Denali Therapeutics (DNLI) Other financing activities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Other financing activities data on file, last reported at $6.7 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 1025.21% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $14.6 million, a 14.17% decrease from a year earlier, with the FY2025 full-year figure at $8.5 million, down 51.35% from the prior year.
• Other financing activities for Q1 2026 stood at $6.7 million, up from $3.2 million in the prior quarter.
• Over the last five years, Other financing activities for DNLI reached as high as $9.0 million in Q2 2023 and fell as low as -$13.1 million in Q4 2023.
• Historically, Other financing activities has averaged $2.8 million across 5 years, with a median of $3.4 million in 2022.
• Across the five-year window, Other financing activities plunged 481.69% in 2023 and surged 1025.21% in 2026, its largest moves.
• Year by year, Other financing activities stood at $3.4 million in 2022, then plunged by 481.69% to -$13.1 million in 2023, then surged by 131.68% to $4.2 million in 2024, then declined by 22.41% to $3.2 million in 2025, then jumped by 107.66% to $6.7 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $6.7 million in Q1 2026, $3.2 million in Q4 2025, and $583000.0 in Q3 2025.